|
|
Experience of British Biotechnology Achievements Transformation and Suggestions |
ZHANG Da-lu |
China National Center for Biotechnology Development |
|
|
Abstract As the second strongest country, UK is taking leading role in biotechnology development around world. UK government supported biotechnology in many ways, such as government policy, tax policy and government investments.We tried to review the policies and experiences since 1950’s, the British Government guidance, input as well as a range of incubation policy, contributed to the achievements of the British biotechnology industry.Considering UK's experiences on biotechnology area, is to make reference to Chinese biotechnology development in the future.
|
Received: 09 April 2012
Published: 25 September 2012
|
|
|
|
[1] 赵清华,范明杰,李玉洁,等. 英国:10%的GDP受益于生物技术应用. 中国生物工程杂志,2008, 28(7):2-5. Zhao Q H, Fan M J, Li Y J, United Kingdom:10 percent of GDP to benefit from biotechnology applications. China Biotechnology, 2008, 28 (7):2-5. [2] Geoffrey O. Entrepreneurship in UK biotechnology: the role of public policy. The Diebold Institute Entrepreneurship and Public Policy Project,2001,14:6-28. [3] Charlotte B. How and when did we get here? an historical institutionalist analysis of EU biotechnology policy. Journal of European Integration, 2011, 34(4):341-357 [4] 李志军. 英国技术集团(BTG)的技术转移. 调查研究报告,2003,52: 1-17. Li Z J. British Technology Group (BTG) technology transfer. Research Reports, 2003,52: 1-17. [5] 孟胜利. 英国生物技术产业的最新进展. 生物技术世界, 2008,6:5-9. Meng S L. The latest progress of the British biotechnology industry. The World of Biotechnology, 2008,6:5-9. [6] Henderson R, Orsenigo L, Pisano G. The Pharmaceutical Industry and the Revolution in Molecular Biology: Exploring the Interactions Between Scientific, Institutional and Organizational Change in The Sources of Industrial Advantages. Cambridge: Cambridge University Press, 1999. 10-18, 24-35, 52-68. [7] Calin Gurau, Leo-Paul Dana, el al. Academic entrepreneurship in UK biotechnology firms: alternative models and the associated performance. Journal of Enterprising Communities: People and Places in the Global Economy, 2012,6(2):154-168. [8] Cockburn I, Henderson R. Public-private interaction in pharmaceutical research. Proc Natl Acad Sci USA, 1996, 93:12725-12730. [9] Goldman M. Industrial biotechnology in the UK: a funder’s perspective Goldman Merlin. Industrial Biotechnology, 2011, 7(4): 269-271. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|